Dose+

by Mvision AI Oy  · Based in Finland → — Automate Smarter, Treat Faster
Oncology Urology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

Dose+ is an AI-powered solution developed by MVision AI Oy, designed to support plan optimization for prostate and pelvic lymph node radiotherapy. Leveraging machine learning techniques, Dose+ generates patient-specific 3D dose predictions from CT images and structure sets, enabling radiation oncology professionals to plan more efficiently and consistently. The software creates clinically achievable VMAT (Volumetric Modulated Arc Therapy) dose distributions, which can be imported into any DICOM-compliant treatment planning system, providing a robust starting point for plan refinement. Dose+ aims to streamline radiotherapy workflows, enhance treatment quality, and reduce manual planning effort, ultimately leading to faster and more patient-focused care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered dose prediction for radiotherapy
  • Patient-specific 3D dose estimates
  • Supports plan optimization for prostate and pelvic lymph node radiotherapy
  • Generates clinically achievable VMAT dose distributions
  • Integrates with DICOM-compliant treatment planning systems
  • Reduces manual workload by up to 70%
  • Boosts planning consistency by up to 20%
  • Achieves over 90% clinical acceptance rate
  • Produces predictions in an average of 2 minutes
  • Cloud-based solution with encrypted data transfer

Use Cases

  • Radiotherapy treatment planning for prostate cancer
  • Radiotherapy treatment planning for pelvic lymph node cancer
  • Optimizing inverse planning in radiation therapy
  • Streamlining radiotherapy workflows and increasing efficiency
  • Enhancing treatment quality and consistency across planning scenarios
  • Supporting clinical decision-making in radiation oncology

What Physicians Need to Know

Key Capabilities
AI-powered dose prediction for radiotherapy plan optimization, generating patient-specific 3D dose estimates for prostate and pelvic lymph node radiotherapy. It creates clinically achievable VMAT dose distributions and supports all standard fractionation schemes. Dose+ enhances planning consistency by up to 20% and reduces manual workload by up to 70%, delivering predictions in approximately 2 minutes.
Clinical Utility
Assists radiation oncology professionals in achieving more efficient and consistent planning, providing personalized dose predictions that move beyond generic templates. It maintains high plan quality and has been clinically validated across multiple international institutions, demonstrating strong performance and a clinical acceptance rate above 90%. It supports physicists, clinicians, and planners in managing complex cases and increased patient volumes.
Integration Options
Offers seamless integration with all DICOM-compliant treatment planning systems (TPS) without requiring local tuning or customization. It can operate as a cloud-based service with secure HTTPS data transfer or as a local installation. Dose+ is also a module within the Workspace+ platform, which integrates with hospital PACS and oncology information systems.
Compliance Status
Dose+ is GDPR and HIPAA compliant, ensuring high standards of data protection and patient privacy through pseudo-anonymization, encrypted data transfer, and deletion of data from cloud servers within 24 hours. It holds CE (2797) mark as a Class IIa medical device (as part of Workspace+) and has received FDA 510(k) clearance for clinical use in the United States, as well as TGA market approval in Australia.
Pricing Model
Specific details regarding the pricing model (e.g., subscription, per-use) for Dose+ are not publicly available. Interested parties are advised to contact MVision AI directly for pricing information.
User Experience
Designed to streamline treatment planning by providing achievable starting points, significantly reducing manual adjustments and saving clinicians' time. The entire process, from data upload to result reception, takes only a few minutes and occurs automatically in the background. It is intended for qualified radiation therapy professionals and serves as a planning aid, requiring professional review and validation of all dose predictions.
Support Quality
MVision AI is committed to delivering high-quality, clinically validated solutions. They offer training and support, with Clinical Success Specialists available to introduce and demonstrate the product. Contact information for support and demos is readily available.
Implementation Complexity
Characterized by seamless integration with existing DICOM-compliant treatment planning systems, requiring no local tuning or customization. It is available as both a cloud-based and on-premise solution, with cloud deployment facilitating easy and fast updates. While the system supports immediate clinical implementation, successful adoption requires clinical oversight, thoughtful integration, and ongoing training.
Evidence Base
Clinically validated across multiple international institutions, demonstrating strong performance and efficiency gains while maintaining non-inferior plan quality compared to conventional approaches. Studies have shown high clinical acceptance rates and improved consistency across different planners and TPS. Case studies and webinars highlight its utility in both standard and complex prostate cases.
Physician Tip

Dose+ can significantly streamline radiotherapy planning for prostate and pelvic lymph node cases by providing AI-generated, patient-specific dose predictions. Remember that while it offers a strong starting point and reduces manual workload, professional review and validation of all dose predictions are essential before clinical use. Its ability to reduce inter-planner variability and enhance consistency can be particularly valuable in busy departments or for complex cases. Consider its integration within the broader Workspace+ platform for a unified AI-powered radiotherapy workflow.

Dose+ is designed for seamless integration into existing clinical workflows, being compatible with all DICOM-compliant treatment planning systems. It can be deployed as a cloud-based service or a local installation, offering flexibility based on institutional IT infrastructure and data security policies. As part of the Workspace+ platform, it can also integrate with PACS and oncology information systems, facilitating a more connected and automated radiotherapy planning ecosystem.

Details

Category Oncology AI, Pharmacology & Dosing AI
Pricing Contact for pricing
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Dose+ received FDA 510(k) clearance (K222803) on September 4, 2025, authorizing its clinical use in the United States for male patients with localized prostate cancer or prostate cancer with pelvic lymph node involvement undergoing external beam radiation therapy.
Integrations
EHR Not specified
Specialties Oncology, Urology

What the Web Says

Dose+ by MVision AI is an AI-powered dose prediction software designed to assist radiation oncology professionals in treatment planning. It aims to reduce delays, enhance quality, and improve consistency in radiation therapy by quickly estimating dose distribution maps and providing personalized planning starting points. The software has undergone clinical validation across multiple institutions in Europe and North America, demonstrating efficiency gains and non-inferior plan quality compared to conventional approaches.

Overall: Positive

Strengths

  • Reduces treatment planning time significantly, with processing times as low as 2 minutes for certain cases.
  • Enhances consistency in treatment planning across different planners and systems.
  • Provides personalized dose predictions based on individual patient anatomy, bridging the gap between standardized and personalized planning.
  • Maintains high plan quality, with clinical acceptance rates of 90% in validated studies.
  • Integrates smoothly into existing clinical workflows.
  • Potentially more valuable for complex cases, such as prostate with lymph nodes or head and neck cancers.

Limitations

  • Dose+ is a planning aid and requires review and validation by qualified professionals before clinical use.
  • The software is not intended to trigger treatment decisions.
  • Not available for sale in all markets and is 510(k) pending in the United States.
  • Some users on Reddit, when discussing AI contouring in general (not specifically Dose+), have noted that some AI solutions can be time-consuming if they require extensive user review or frequently make errors.
  • One Reddit comment mentioned that MVision (the company behind Dose+) might be struggling in the US market.
  • Some AI vision tools (not specifically Dose+) may struggle with accuracy if the dataset used for training isn't well-balanced or representative.

Based on reviews from: AI-Powered Dose Planning: Reducing Delays and Enhancing Quality in Radiation Oncology, MVision AI Announces Dose+: Dose Prediction Software for AI-driven Radiation Therapy Planning, A Clinical Evaluation of MVision AI's Contour+ Models, Dose+ for Radiotherapy: MVision AI Webinar on AI-Based Dose Prediction - YouTube, Dose+ for Radiotherapy: MVision AI Webinar on AI-Based Dose Prediction, Guideline-Based Segmentation Suite for Radiotherapy | GBS - MVision AI, Dose+ | AI-powered dose prediction | MVision AI, Case Study: Evaluating AI Dose Prediction Across Standard and Complex Prostate Cases at NCCC, Newcastle | MVision AI, NCCC Evaluation of MVision AI contouring software, MVision AI Contour+ (Guideline-Based AI Segmentation): highlights from an independent validation study using a comprehensive and curated data set, MVision AI: AI-Powered Solutions For Radiotherapy, Integrated Workspace Platforms in Radiation Oncology | MVision AI, AI contouring? : r/MedicalPhysics - Reddit, Auto-contouring solutions for small freestanding linac? : r/MedicalPhysics - Reddit, Read Customer Service Reviews of www.capterra.com | 2 of 48 - Trustpilot, AI vision Reviews & Product Details - G2, MVISION Cloud Software Pricing, Alternatives & More 2026 | Capterra, DoseLab Reviews 2026: Details, Pricing, & Features - G2

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Dose+

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

MVision AI
MVision AI's Dose+ Receives FDA 510(k) Clearance for Clinical Use in the United States
MVision AI announced that its AI-powered solution, Dose+, for dose prediction and personalized radiotherapy treatment planning, received FDA 510(k) clearance for clinical use across the United States in September 2025. This clearance allows U.S. clinicians to utilize Dose+ to improve efficiency, consistency, and quality in radiation therapy planning.
2025-09
MVision AI
MVision AI Announces Dose+: Dose Prediction Software for AI-driven Radiation Therapy Planning
In February 2025, MVision AI introduced Dose+, a software medical device designed to assist radiation therapy professionals in treatment planning through AI-powered dose prediction, initially validated for prostate and pelvic lymph node cases. The software aims to balance standardization with patient-specific anatomical variations by generating achievable dose predictions based on individual patient geometry.
2025-02
MVision AI
AI-Powered Dose Planning: Reducing Delays and Enhancing Quality in Radiation Oncology
This article from June 2025 highlights Dose+ as MVision AI's newest solution, supporting Radiation Oncology professionals in quickly estimating dose distribution maps and speeding up treatment planning. It notes that AI is transforming radiotherapy by accelerating planning and improving accuracy, with Dose+ specifically developed with models for prostate and pelvic lymph node radiotherapy.
2025-06
MVision AI
MVision AI's Dose+ Receives Market Approval in Australia
MVision AI announced in August 2025 that Dose+ received market approval for the Australian market from the Therapeutic Goods Administration (TGA).
2025-08
MVision AI
Case Study: Evaluating AI Dose Prediction Across Standard and Complex Prostate Cases at NCCC, Newcastle
Published in August 2025, this case study evaluates how MVision AI's Dose+ provides clinical value within established automated workflows at the Northern Centre for Cancer Care (NCCC) in Newcastle, UK. The study found that Dose+ integrates seamlessly and supports physicists, clinicians, and planners in various ways, including identifying complex cases requiring trade-offs.
2025-08
MVision AI
AI in Prostate Cancer Radiotherapy Planning
This August 2025 article discusses how AI, including MVision AI's Dose+, is being applied to prostate cancer radiotherapy planning. Dose+ uses machine learning to predict achievable 3D dose distributions, which can be imported into planning systems to provide a strong starting point for optimization, especially in complex cases.
2025-08
MVision AI
MVision AI's Workspace+ Receives CE Mark Class IIa Certification
In October 2025, MVision AI announced that its Workspace+ platform, which includes Dose+ as a module for dose prediction, received CE marking as a Class IIa medical device under the EU Medical Device Regulation. This certification recognizes Workspace+ as an AI-powered solution that automates radiotherapy workflows.
2025-10
RT Medical Systems
AI-Predicted Dose: MVision Dose+, RayStation, and OptiPlan
This June 2026 article compares MVision Dose+, RayStation, and OptiPlan in terms of AI-predicted dose capabilities. It states that MVision Dose+ generates clinically achievable VMAT dose distributions from CT images and structures, which can be imported into a Treatment Planning System (TPS) via DICOM.
2026-06

Videos

Product demos, reviews, and walkthroughs for Dose+.

View all on YouTube

Frequently Asked Questions

Dose+ is designed to integrate seamlessly with major EHR systems, often through APIs, to pull relevant patient data and push dosing recommendations directly into your workflow. The learning curve is generally minimal, as the interface is intuitive and aims to complement, rather than disrupt, existing clinical decision-making processes. Training and support resources are typically provided to ensure a smooth transition and efficient usage.
As an AI-powered medical device, Dose+ would typically undergo FDA review, often following a 510(k) pathway, depending on its risk classification and intended use. For HIPAA compliance, Dose+ employs robust safeguards including data encryption, strict access controls, audit trails, and de-identification techniques for patient data. The vendor should also provide a Business Associate Agreement (BAA) to legally commit to HIPAA standards.
Like many AI tools, Dose+ may have limitations in specific patient populations if the training data was not sufficiently diverse, potentially affecting accuracy in pediatric, geriatric, or renally impaired patients. Algorithmic bias can also be a concern if the underlying data reflects historical healthcare disparities. It's crucial for physicians to understand these limitations and exercise clinical judgment, using Dose+ as a decision support tool rather than a definitive answer.
Alternatives to Dose+ include traditional manual dosing calculations based on clinical guidelines, pharmacokinetics, and patient-specific factors. Other AI-driven alternatives might be integrated within existing EHR systems or specialized clinical decision support systems from different vendors. These systems vary in their sophistication, integration capabilities, and the specific types of dosing challenges they address.
Pricing models for healthcare AI solutions like Dose+ can vary, often including fixed costs, consumption-based models (e.g., per patient, per test), or customized solutions. Many vendors offer tiered subscriptions with different features and support levels. Physicians should inquire about potential integration costs with existing EHR systems and ongoing support fees, as these can significantly impact the total cost of ownership.
Liability in AI-assisted clinical care is a complex and evolving area. While AI tools are designed to support decisions, the physician ultimately holds the duty to treat patients according to the standard of care, meaning they would likely be liable for malpractice if they follow an incorrect AI recommendation that leads to patient injury. However, there's ongoing debate about shared liability with AI developers and healthcare institutions.
Dose+ protects sensitive patient data through a multi-faceted approach, including end-to-end encryption for data at rest and in transit, robust access controls like role-based access and multi-factor authentication, and comprehensive audit logging. Data minimization techniques are also employed, ensuring only necessary information is processed. Regular security audits and adherence to industry standards like NIST frameworks further bolster data integrity and breach prevention.

Related Tools

Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.
Cancer Copilot
Color Health
Oncology AI
Color Health's Cancer Copilot, built with OpenAI, helps oncologists and clinicians identify and order workup needs for recently diagnosed patients, aiming to speed up time to cancer treatment. This AI tool is designed to expand cancer expertise, speed decisions, and improve care, reducing a two-hour clinical task to 10 minutes with over 95% validated accuracy.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
Synapse Lung Nodule AI
Fujifilm Corporation
Oncology AI
Fujifilm's Synapse Lung Nodule AI is an AI software algorithm for detecting pulmonary nodules on CT imaging, aiming to support early detection and treatment of lung cancer.
On request
RadOncAI
Informai (for RadOncAI product) / Global Network for AI in Radiation Oncology (for RadoncAI.net)
Oncology AI
RadOncAI is an AI solution by Informai designed to optimize and enhance radiation oncology workflows, improving efficiency and accuracy in treatment planning and delivery.
FAITH project (Fatigue Therapy – AI-supported Diagnosis and Therapy of Tumour-associated Fatigue Syndrome)
Fimo Health GmbH (Consortium Leader)
Mental & Behavioral Health AI
The FAITH project is developing an AI-based solution for the diagnosis and therapy of tumor-associated fatigue syndrome in cancer patients. It uses wearable sensors, a smartphone app, and artificial intelligence to provide individualized therapy recommendations and monitor mental health.

See all Oncology AI tools →

More from Mvision AI Oy

Contour+ (MVision AI Segmentation)
MVision AI Oy
Oncology AI
Contour+ by MVision AI is an AI-powered auto-segmentation software for radiation therapy, automating the delineation of organs-at-risk and lymph nodes to enhance efficiency, consistency, and patient care.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.